Glaukos submits NDA to US FDA for Epioxa for the treatment of keratoconus

News
Article

If approved, Glaukos states that Epioxa would be the first FDA-approved, non-invasive corneal cross-linking therapy that does not require removal of the corneal epithelium.

Glaukos submits NDA to FDA for iLink Epioxa - Image credit: Adobe Stock / ©Araki Illustrations

Image credit: Adobe Stock / ©Araki Illustrations

Glaukos has announced the submission of its US FDA New Drug Application (NDA) for Epioxa, a next generation corneal cross linking iLink therapy for the treatment of keratoconus. The NDA submission includes data from 2 Phase 3 pivotal trials of Epioxa, both of which achieved their primary efficiency endpoints and demonstrated favorable tolerability and safety, according to a news release.

"The NDA submission for Epioxa represents an important milestone for our company as it brings us one step closer in being able to provide keratoconus patients and the ophthalmic community with the first FDA-approved, non-invasive corneal cross-linking drug therapy that does not require removal of the corneal epithelium, the outermost layer of the front of the eye,” said Thomas Burns, Glaukos chairman and chief executive officer, in the release. “We look forward to working closely with the FDA in their pending review process and continue to believe Epioxa, which is designed to reduce procedure times, improve patient comfort and shorten recovery time, represents a potentially meaningful advancement in the treatment paradigm for patients suffering from keratoconus.”

Epioxa utilizes a proprietary, novel drug formulation which is designed to penetrate the epithelial layer of the cornea. This provides a stronger UV-A irradiation protocol and supplemental oxygen to enhance cross-linking. This design allows Epioxa to preserve the corneal epithelium, reduce procedure times, improve patient comfort, and shorten recovery time, according to the release

If approved, Glaukos states that it anticipates Epioxa as the first FDA-approved, non-invasive corneal cross-linking therapy that does not require removal of the corneal epithelium.

Reference
1. Glaukos submits New Drug Application to US FDA for Epioxa. News release. Glaukos. December 23, 2024. Accessed December 23, 2024. https://www.businesswire.com/news/home/20241223560924/en/Glaukos-Submits-New-Drug-Application-to-U.S.-FDA-for-Epioxa%E2%84%A2

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Melissa Barnett, OD, FAAO, FSLS, FBCLA, gave 2 presentations alongside other ODs and MDs at CRU 2025.
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
OptiLIFT in action: Dr. Julie McLaughlin's experience with the new device
Dr. Nate Lighthizer shares key takeaways from the SECO Showcase on anterior segment technology and full laser certification course offered at SECO.
Dr. Mile Brujic discusses a case series on a novel gel for lacrimal occlusion.
Three EnVision Summit faculty members weigh in on the importance of comanagement in glaucoma management, where artificial intelligence will lead eye care, and what hopes are on the horizon for corneal ectasia treatments.
Dr Jamie Kuzniar discusses higher order aberrations and premium scleral lenses
© 2025 MJH Life Sciences

All rights reserved.